Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Evotec, BMS Advance Targeted Protein Degradation Projects | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Evotec, BMS Advance Targeted Protein Degradation Projects

The first two targets transition into drug discovery after completing a comprehensive target validation process.

By: Contract Pharma

Contract Pharma Staff

Evotec has achieved key milestones in its partnership with Bristol Myers Squibb in the field of targeted protein degradation with the first two targets transitioning into drug discovery after completing a comprehensive target validation process.
 
The companies entered a long-term strategic discovery and development partnership in 2018 with the goal to identify novel drug targets. The partnership leverages Evotec’s PanOmics platform, which combines enhanced throughput proteomics, high throughput transcriptomics and cell imaging with an integrated data analysis platform PanHunter. This has enabled the generation of a pipeline of novel first-in-class targeted protein degradation projects.
 
The first two projects have now transitioned into lead optimization following validation on Evotec’s platforms. Targeted degradation of these novel targets impacts an established cancer pathway with the promise of providing new therapeutic options for difficult-to-treat breast cancers. Evotec will be responsible for progressing the drug discovery programs to IND filing.
 
Evotec receives undisclosed milestone payments as well as research funding for the further development of the programs and can earn further success-based milestones. Additionally, Evotec is entitled to royalties on sales of programs developed under the partnership.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics